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Background: Inflammatory cell infiltration and residual areas of fibrosis in kidneys after renal transplantation can
lead to functional abnormalities with long-term implications.
Objectives: The aim of this study was to determine urinary monocyte chemoattractant protein-1 (uMCP-1) levels,
relative cortical interstitial area (RCIA), and cortical tubulointerstitial macrophage infiltration in renal transplant
patients with delayed graft function (DGF) and their possible correlation with graft outcome.
Design: Patients were followed after biopsies for one year, and their renal function and structure were evaluated, as
well as parameters of inflammatory process.
Setting: Clinical Hospital of the School of Medicine of Ribeirão Preto.
Patients: Twenty-two cadaveric kidney transplant recipients with DGF were followed for one year.
Measurements: Renal function, RCIA, macrophages infiltration and uMCP-1 levels were evaluated.
Methods: Renal function was evaluated by plasma creatinine levels. RCIA was determined by morphometry.
Immunohistochemical staining of macrophages was performed using an anti-CD68 monoclonal antibody. uMCP-1
levels were determined using a human MCP-1/CCL2 immunoassay kit.
Results: There was a significant increase in uMCP-1 levels in transplant patients compared with controls (p < 0.001).
RCIA was 7.1% (6.4 to 9.2; median and 25th to 75th percentiles) in controls and 37.1% (28.1 to 43.7) in patients with
kidney transplants (p < 0.001). The patients who presented with a higher RCIA in the first biopsy showed higher levels of
plasma creatinine one year after transplantation (r = 0.44; p < 0.05). The number of tubulointerstitial macrophages per
0.10 mm2 grid field was higher in the renal cortex of transplant patients compared with the controls (19.4 (9.0 to 47.1)
vs. 2.5 (1.8 to 3.4), p < 0.001). There was also a positive correlation between the RCIA and the number of tubulointerstitial
macrophages in the renal cortex of these patients (r = 0.49; p < 0.001).
Limitations: The number of patients studied was relatively small and may not be reflecting outcomes over a larger
spectrum of kidney cadaveric transplants.
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Conclusions: Our results demonstrate increased levels of uMCP-1 in transplant patients with DGF, in addition to
increased tubulointerstitial macrophage infiltration and RCIA, which could predict the outcome of renal function in
these patients.
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Contexte: L’infiltration de cellules inflammatoires et la présence de zone de fibrose résiduelle, après la transplantation
rénale, peuvent entraîner des anomalies fonctionnelles ayant des incidences à long-terme.
Objectifs: Le but de cette étude était de déterminer, chez les patients transplantés avec retard de fonctionnement du
greffon (RFG), les taux urinaires de protéine chimiotactique monocytaire-1 (uMCP-1), la zone relative de l’interstitium
cortical, et l’infiltration tubulo-interstitielle de macrophages dans le cortex rénal afin d’évaluer la possible corrélation de
ses informations et de l’évolution de la transplantation.
Type d’étude: Les patients ont été suivis pendant un an, après biopsie, avec évaluations stucturelle et fonctionnelle,
et évaluation des paramètres du processus inflammatoire.
Contexte: Hôpital clinique de l’école de médecine de Ribeirão Preto.
Patients: Vingt-deux patients ayant reçu un greffon rénal cadavérique avec RFG ont été suivis pendant un an.
Mesures: La fonction rénale, l’infiltration de macrophages et les taux d’uMCP-1 ont été évalués.
Méthodes: La fonction rénale a été évaluée en utilisant les concentrations sériques de créatinine. Une coloration
immunohistochimique des macrophages par anticorps monoclonal anti-CD68 a été effectuée. Les concentrations
d’uMCP-1 ont été déterminées en utilisant les tests immunologiques de MCP-1/CCL2 humaine.
Résultats: Les concentrations d’uMCP-1 étaient significativement plus élevées chez les patients transplantés que chez
les sujets du groupe témoin (p < 0.001). Les médianes de la zone relative de l’interstitium cortical étaient de 7,1%
(25ème au 75ème percentiles : de 6,4% à 9,2%) pour le groupe témoin et de 37,1% (de 28,1% à 43,7%) chez les
patients transplantés rénaux (p < 0.001). Les patients ayant une la zone relative de l’interstitium cortical plus grande au
moment de la première biopsie présentaient une concentration plasmatique de créatinine plus grande un an après la
transplantation (r = 0.44; p < 0.05). Le nombre de macrophages dans l’espace tubulo-interstitiel, par champs de 0,10
mm2, était plus élevé dans le cortex rénal des patients transplantés que chez le groupe témoin (19,4 (de 9.0 à 47.1) et
2,5 (de 1.8 à 3,4), p < 0.001). Il existait également une corrélation positive entre la zone relative de l’interstitium cortical
et le nombre de macrophages dans l'espace tubulo-interstitiel du cortex rénal de ces patients (r = 0.49; p < 0.001).
Limites de l’étude: l’échantillon étudié était relativement petit et ne représente pas nécessairement les résultats d’un
échantillon plus vaste constitué de patients transplantés avec greffon rénal cadavérique.
Conclusions: Nos résultats démontrent des concentrations d’uMCP-1 plus élevées chez les patients avec RFG,
accompagnées d’une infiltration de macrophages dans l’espace tubulo-interstitiel et d’une zone relative de l’interstitium
cortical plus grandes, faits qui pourraient prédire l’évolution de la fonction rénale chez ces patients.What was known before
It has been observed that recovery of renal function after
cadaveric transplantation with delayed graft function
(DGF) is typically slow and may be incomplete. Increased
monocyte chemoattractant protein-1 (MCP-1) levels have
been observed in urine from patients during acute renal
graft rejection compared with those with stable graft func-
tion. We found in previous studies that there was a large
increase in α-smooth muscle-actin (α-SMA), fibronectin,
and endothelin expression in the tubulointerstitial com-
partment of kidneys from patients with acute tubular ne-
crosis after renal transplantation, which was associatedwith increased urinary levels of transforming growth fac-
tor β (TGF-β). These findings may explain the impaired
recovery of renal function observed in these patients.What this adds
This study shows that increases in the urinary levels of
MCP-1, relative cortical interstitial area (RCIA), and
macrophage infiltration in the renal cortex could pre-
dict the evolution of renal lesions in patients with acute
tubular necrosis following renal transplantation with
DGF.
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Renal function recovery after cadaveric transplantation
with DGF is normally slow, occurring after 4–6 weeks,
and may be incomplete because of acute tubular necrosis
and/or rejection that lead to significant loss of nephron
mass [1]. Previous studies have demonstrated persistent
areas of fibrosis after renal function recovery following
acute tubular necrosis [2,3]. Interstitial fibrosis is a com-
plex process that involves the interaction between cells
and cytokines and results in the accumulation of fibro-
blasts and extracellular matrix (ECM) in the interstitial
space [4-8]. In a previous study, we demonstrated that
there was a dramatic increase in the expression of
α-smooth muscle-actin (α-SMA), fibronectin and endothe-
lin in the tubulointerstitial compartment of the kidneys
from patients with acute tubular necrosis post-renal trans-
plantation. These findings were associated with higher
levels of nuclear factor-κB (NF-κB) and phosphorylated
c-jun N-terminal kinase (p-JNK) in tubular and interstitial
cells from the renal cortex of these patients [9]. NF-κB and
p-JNK participate in the progression of renal lesions in
several experimental models of nephropathy by inducing
the synthesis and release of inflammatory substances,
promoting macrophage infiltration and cell transdiffe-
rentiation [9]. We also detected an increase in urinary
transforming growth factor-β (TGF-β) excretion in trans-
plant patients with DGF who received a cadaveric kidney.
TGF-β is considered by most researchers the principal
profibrogenic cytokine [6,8]. TGF-β can transform fibro-
blasts, tubular and mesangial cells into myofibroblasts that
start to express α-SMA and have increased production of
several ECM proteins [5].
Macrophages contribute to renal injury by releasing
cytokines (TGF-β, endothelin, interleukin 1), angiotensin
II and free radicals as well by producing several ECM
components. Macrophages also play an important role
in tissue homeostasis and remodeling, and are potent
immune regulators [10]. Macrophages accumulate in
the renal tissue during the early stages of ischemia-
reperfusion injury and have a pivotal role in both innate
and adaptive responses to the graft [11].
Monocyte chemoattractant protein-1 (MCP-1) is a po-
tent proinflammatory chemokine that acts by binding to
the C-C chemokine receptor 2 (CCR2) [12]. MCP-1 me-
diates changes in the shape, expansion and subsequent
transendothelial migration of monocytes/macrophages
[12]. MCP-1 has a strong chemotactic action on ma-
crophages and has been associated with macrophage
infiltration and injury in several renal diseases [13].
These data suggest that MCP-1 may be useful as a bio-
marker for monitoring the outcome of allografts in pa-
tients with DGF.
The aim of this study was to determine urinary MCP-1
(uMCP-1) levels, macrophage infiltration and RCIA ofpatients who underwent renal transplantation with DGF
and their possible correlation with graft outcome.
Methods
Subjects
The study was approved by the Human Ethical Committee
of the Clinical Hospital from School of Medicine of
Ribeirão Preto (Protocol no 154405/2005). All participants
provided written informed consent. Twenty-nine patients
who underwent cadaveric renal transplantation and had
DGF over the course of a two-year follow-up period were
studied. The study took place in the Clinical Hospital of
the School of Medicine of Ribeirão Preto. After biopsies
were taken, the patients were followed for one year, and
their renal function was evaluated by measuring plasma
creatinine levels. Fresh urine was collected up to two days
before or after renal biopsy to measure uMCP-1 levels.
The patients with DGF were defined as those who re-
quired dialysis after transplantation.
Preserved areas of normal renal tissue from 10 pa-
tients undergoing nephrectomy for the localization of
renal tumors were used as controls (n = 10 patients).
This renal tissue was obtained from the macroscopically
normal areas of the kidney located at some distance
from the neoplastic process. After excluding patients
with a history of hypertension or diabetes, controls were
selected randomly after matching for age and sex, and
confirming that renal tissue did not have any histological
changes (interstitial fibrosis, tubular atrophy, inflamma-
tory cell infiltration or glomerulosclerosis). The age of
control patients ranged from 35 years to 55 years (mean,
48 years), and included seven males and three females.
All of the control subjects were normotensive and had
normal levels of plasma creatinine and 24 h proteinuria
levels (<150 mg).
Histology and morphometry
Renal biopsies were obtained from patients only upon
clinical indication. If the renal function of patients did
not improve, we repeated the biopsies to check if there
was a change in the histological kidney pattern (Table 1).
Nineteen patients underwent the first renal biopsy in the
first three months following surgery and seventeen of
these patients underwent more than one biopsy because
of a lack of improvement of renal function (median = 2.5;
maximum 4, minimum 1). Renal tissue was fixed in
Bouin’s solution for 4–6 h and processed for paraffin em-
bedding. Four-micrometer-thick histological sections were
stained with Masson’s trichrome or hematoxylin and eosin
and examined by light microscopy. RCIA of the renal
cortex was determined by morphometry with a light cam-
era connected to an image analyzer (Axio Vision, Carl
Zeiss, Göttingen, Germany). Fifteen consecutive grid fields
measuring 0.100 mm2 were evaluated in the renal cortex
Table 1 Clinical data of cadaveric renal transplant recipients with delayed graft function
Age (years) Time on dialysis (months) Time of cold ischemia (h) Length of DGF (days) Plasma creatinine levels
after 1 year (μmol/L)
Mean 47 ± 12.0 41.7 ± 34.8 28.2 ± 5.5 16.9 ± 13.2 144.9 ± 43.3
Range 27-71 03-132 16-38 0-46 79.5-229.8
Data are expressed as means ± SD.
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The encircled interstitial areas were manually traced on a
video screen and evaluated by computerized morphometry.
Immunohistochemistry for detection of macrophages
Kidney biopsies from 10 control individuals and 53 biop-
sies from the 22 patients who underwent cadaveric kidney
transplantation with DGF were evaluated. The biopsy tis-
sues were embedded in paraffin and sections stained using
an indirect immunoperoxidase technique. Immunohisto-
chemical studies were performed using a monoclonal
mouse antibody to an antigen present in the cytoplasm of
human monocytes and macrophages (CD68, clone KP1,
IgG1, DAKO, Glostrup, Denmark) as the primary anti-
body. Briefly, serial 4-μm-thick sections were treated with
0.01 M citrate buffer (pH 6.0) in a pressure cooker for
40 min. The sections were then incubated with CD68
antibody (1:200) for 2 h at room temperature, followed by
incubation with the NovoLink™ Max Polymer Detection
System–Post Primary Block (Novocastra Laboratories
Ltd., Newcastle Upon Tyne, UK). After three washes with
Tris buffer containing Tween 20 (0.05%), the sections
were incubated with the NovoLink polymer for 30 min at
37°C. Chromogen development was performed with 3,3′-
diaminobenzidine (DAB; Sigma Chemical Co., St Louis,
MO, USA), and the sections were counterstained with
Harris’ hematoxylin, dehydrated and mounted. The nega-
tive controls were prepared by omitting the primary anti-
body in the reaction.
To evaluate the macrophage numbers in areas of the
cortical tubulointerstitium (TI), at least 15 consecutive
fields were measured. The arithmetic mean of the num-
ber of macrophages/0.10 mm2 of the TI area of all of the
fields examined was used to express the number of mac-
rophages in the renal cortical interstitium of each kid-
ney. The number of macrophages/glomerular tuft (GT)
area was reported as the median of the number of mac-
rophages/GT for each biopsy.
Urinary MCP-1 determination
Fresh urine was collected up to 2 days before or after
the renal biopsy and centrifuged to remove cells and
debris. Aliquots were stored at −70°C after the addition
of 1 N NaOH (to reach a pH between 7.0 and 8.0) and
10 μl of 0.1 M phenylmethylsulfonyl fluoride protease
inhibitor (Sigma-Aldrich Chemie GmbH, Steinheim,
Germany). uMCP-1 levels were determined with theQuantikine Human MCP-1/CCL2 Immunoassay kit
(R&D Systems, Minneapolis, MN, USA). The uMCP-1
values obtained were normalized to the amount of cre-
atinine in the urine sample and reported as the ratio of
uMCP-1 (pg/ml)/urinary creatinine (mg/ml). Urine sam-
ples from 10 healthy individuals were used as controls.
The urinary biomarker measurements in the controls
were performed in the same period used for the patients
in this study.
Statistical analysis
Data are reported as medians plus percentiles (25th to
75th). Groups were compared using the Mann–Whitney
U Test. Correlation coefficients for regression analysis
were determined using the Spearman coefficient (r) for
nonparametric data. Statistical analyses were performed
using Graph Pad Prism version 5.0 for Windows, Graph
Pad Software, San Diego, California, USA. In all cases, a
P-value of p < 0.05 was considered statistically significant.
Results
Subjects
Twenty-nine patients (18 males and 11 females) who
underwent renal cadaveric transplantation and had DGF
were initially enrolled in the study, although only twenty-
two patients were studied. Seven patients (4 males and
3 females) were excluded from the study because of either
the loss of the graft, transfer to another center or death
before the first year of follow up. Twenty patients started
immunosuppression with sodium mycophenolate and
tacrolimus, fourteen received induction therapy with basi-
liximab and nine changed from tacrolimus to sirolimus
during the first year post-transplantation because of suspi-
cion of nephrotoxicity or chronic allograft nephropathies.
Two patients started immunosuppression with cyclospo-
rine A and basiliximab, and both converted to sirolimus
during the first year post-transplant. The clinical data
from the 22 patients studied are shown in Table 1.
Histology
A total of 53 biopsies were examined, with a median of
2.5 biopsies (1.7 to 5.0; median and 25th to 75th percen-
tiles) per patient. Light microscopy showed morpho-
logical features characteristic of acute tubular necrosis
(defined as tubular cell necrosis and tubular lumen dila-
tion) in 18 biopsies from 9 patients (Banff 6), features of
nephrotoxicity due to drugs in 9 biopsies from 9 patients
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from 13 patients (Banff 5; 12 grade I, 2 grade II and 3
grade III), normal tissue in 8 biopsies from 5 patients,
and acute cellular rejection in 1 biopsy from 1 patient
(Table 2). Most of the biopsies had unchanged glomeru-
lar morphology, and the mean number of glomeruli in
each biopsy was 14.3 ± 9.0. The median time of biopsy
after transplantation was 47 (6 to 126) d.Figure 1 Correlation between the relative cortical interstitial
area (RCIA) and interstitial macrophages in the renal cortex
tubulointerstitial area of renal cadaveric transplant recipients
with delayed graft function (DGF). (r = 0.49; p < 0.001).Morphometry
An increase in RCIA was observed in kidney transplant
patients with DGF. RCIA was 7.1% (6.4 to 9.2) in the
control group and 37.1% (28.1 to 43.7) in the patients
with kidney transplants (p < 0.001). A higher RCIA in
the first biopsy was correlated with higher serum creatin-
ine levels one year after the transplant (r = 0.44; p < 0.05).
There was also a correlation between the RCIA and the
number of interstitial macrophages (r = 0.49; p < 0.001)
(Figure 1). We found in previous studies that an increase
in RCIA is correlated with inflammation and fibrosis,
which contributes to renal disease progression [9].Urinary MCP-1 levels
There was a significant increase in the uMCP-1 levels of
transplant patients with DGF compared with controls
(p < 0.001, Figure 2). However, there was no difference in
uMCP-1 levels between patients with histological fin-
dings of acute tubular necrosis (n = 9) and patients with
chronic alterations (n = 13).Immunohistochemical studies
There was a significant increase in the number of tubu-
lointerstitial macrophages in the renal cortex in transplant
patients compared with controls (p < 0.001, Figure 3). The
number of tubulointerstitial macrophages per 0.100 mm2
was 2.5 (1.8 to 3.4) in controls and 19.4 (9.0 to 47.1) in the
cortex of kidney transplant patients (Figure 4). There was
no difference in the number of macrophages in the glom-
erular tufts of the kidney biopsies from the transplant pa-
tients compared with the control individuals.Table 2 Histological data obtained from light microscopy
of 55 patient biopsies
Morphological features Number of
biopsies
Number of
patients
Acute tubular necrosis 18 7
Suggestive of nephrotoxicity due to drugs 9 9
Chronic nephropathy of the graft 17 13
Acute cellular rejection 1 1
Normal tissue 8 5Discussion
MCP-1/chemokine (C-C) motif ligand 2 (CCL2) is a po-
tent proinflammatory chemokine that acts by binding to
the C-C chemokine receptor 2 (CCR2). MCP-1 mediates
changes in the transendothelial migration of monocytes/
macrophages [12], has a strong chemotactic action on
macrophages, and has been shown to promote macro-
phage infiltration and injury in several renal diseases
[13]. In animal models, blocking MCP-1/CCL2 or CCR2
is associated with reduced interstitial macrophage infil-
tration and tubulointerstitial damage [14-16]. We found
a significant increase in uMCP-1 in patients who under-
went cadaveric transplantation with DGF compared with
controls, suggesting the presence of active renal disease
and inflammatory processes, especially in the early days
post-transplantation when the majority of biopsies wereFigure 2 uMCP-1 (pg/ml)/urine creatinine (mg/100 ml) ratio of
the control individuals and renal cadaveric transplant recipients
with delayed graft function (DGF). Values are expressed as medians
and percentiles (25th; 75th), ***p < 0.001.
Figure 3 Immunolocalization of CD68+ macrophages in the renal cortex of kidneys (A) from a renal cadaveric transplant recipient with
delayed graft function and (B) a control individual.
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uMCP-1 concentration was present among the patients.
The excretion of MCP-1 most likely varies according to
the renal pathology and the inflammatory activity.
The increase in MCP-1 in the urine of transplant pa-
tients with DGF was associated with a significant increase
in tubulointerstitial macrophages and RCIA in these pa-
tients compared with controls. We previously found a sig-
nificant correlation between the RCIA and inflammation in
the tubulointerstitium [9]. Therefore, this is an important
finding that could also be associated with higher uMCP-1
levels. Eardley et al. [17] observed a close association bet-
ween albuminuria, urinary MCP-1/CCL2 and interstitialmacrophage infiltration with in situ damage and the
clinical outcomes of patients with different glomerular
diseases. Dantas et al. [18] showed increased uMCP-1
correlated with proteinuria and interstitial macrophage
infiltration in patients with glomerulopathies. An increase
in MCP-1 was also observed by Dubinsk et al. [19] and
Prodjosudjadi et al. [20] in the urine from patients during
acute renal graft rejection compared with stable graft func-
tion. The authors suggested that the increase in urinary
excretion of MCP-1 is most likely the result of local pro-
duction by tubular epithelial cells. MCP-1 produced locally
may, at least in part, be responsible for the influx of macro-
phages into the interstitium during graft rejection.
Figure 4 Macrophage numbers in the tubulointerstitial area of
the renal cortex from the control individuals and renal cadaveric
transplant recipients with delayed graft function. Values are
expressed as medians and percentiles (25th; 75th), ***p < 0.001.
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area of the renal cortex within the transplanted kidney
has been documented throughout all stages of kidney
transplantation: ischemia-reperfusion injury, kidney re-
covery and establishment of function, the maintenance
phase and chronic allograft nephropathy [11]. The roles
played by macrophages include the promotion of inflam-
mation in response to ischemia-reperfusion injury, pre-
sentation of donor antigens to primed recipient T cells,
mediation of kidney damage during acute rejection,
clearance of cellular debris, modulation of ECM, promo-
tion of fibrosis and regulation of immune responses [11].
Macrophages can contribute to the innate immune re-
sponse in renal ischemia-reperfusion injury, causing cell
damage and inflammation. However, macrophages can
also promote healing and repair as the graft recovers
from acute insults and can be involved in the detrimen-
tal development of interstitial fibrosis and tubular atro-
phy [11]. We did not observe any differences between
the numbers of macrophages in the glomerular tufts of
kidney biopsies from the transplant patients compared
with the control individuals. This finding shows that in-
flammatory process is located only in tubule interstitial
area from the kidney of these patients.
Resident and infiltrating macrophages play a central role
in innate immune protection, through both the clearance
of infective pathogens and repair of tissue injury that oc-
curs, in part, as a consequence of this response [21,22]. Is-
chemia and reperfusion results in apoptosis and necrosis
[23], and the free radicals produced by damaged tissues
may induce the release of inflammatory substances, such
as endothelin, and chemotactic factors for both macro-
phages (MCP-1) and lymphocytes [24-26]. Macrophages
are able to produce profibrogenic cytokines (TGF-β,PDGF, endothelin) and angiotensin, contributing to renal
fibrosis and impairing renal function recovery [5,9,27].
Upon cytokine stimulation, macrophages and renal re-
sident cells may be transformed into myofibroblasts,
express α-SMA and start to produce more collagen and
other ECM components, such as fibronectin [5,9,28].
Additionally, macrophages and resident cells transformed
into myofibroblasts after activation became capable of
synthesizing TGF-β at different stages during the develop-
ment of renal fibrotic lesions [29].
Previously, we demonstrated that the NF-κB complex
was activated in the renal tubular and interstitial cells of
transplanted kidneys with DGF [9]. NF-κB activation
may play an important role by inducing the synthesis of
inflammatory substances, such as cytokines, growth
factors and chemotactic factors for macrophages and
monocytes that provoke renal damage in renal and
extra-renal cells. Chronic allograft alterations, charac-
terized by interstitial fibrosis, tubular atrophy and a de-
crease in renal function, are the major cause of graft loss
[11]. The pathogenesis of these alterations remains un-
clear; however, inflammation is a consistent feature [30].
Experimental and clinical studies provide supportive evi-
dence that macrophages contribute to the development
of kidney disease progression [11]. Pilmore et al. [31]
found that the degree of macrophage infiltration in early
biopsies was predictive of the subsequent development
of alterations in renal function and structure. We have
shown that there was a correlation between the RCIA
and renal function one year after transplantation and
between the RCIA and macrophage infiltration in the
renal cortex. Despite the immunosuppressive agents
used by the transplant patients, macrophage infiltration
and urinary MCP-1 excretion were major features within
the transplanted kidney.
Delayed graft function after renal transplantation re-
mains a problem, and patients with DGF often require
dialysis in the first days post-transplant. DGF includes a
spectrum of clinical manifestations ranging from border-
line function to a complete absence of graft function
[32]. Furthermore, cold ischemia/reperfusion is strongly
associated with DGF [33].
Our study has some limitations, as we cannot exclude
the influence of the renal tumor on the preserved area
of nephrectomized kidneys used as the control group.
The inflammation caused by the tumor cells may also
be present in preserved areas of kidney biopsy. How-
ever, there was no histopathological or immunohisto-
chemical evidence of this effect in the control biopsies.
Moreover, this type of renal tissue has been used as the
control tissue in multiple studies [9,34]. The best con-
trol renal tissue would be from renal transplant patients
without DGF; however, we do not routinely biopsy
these patients.
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In conclusion, the increase in uMCP-1 levels, as well as
macrophage infiltration in the renal cortex interstitial
area and RCIA, may help to predict the outcome of
renal function in cadaveric renal transplant recipients
with DGF. However, this study evaluated only a small
number of patients. Future studies with larger patient
cohorts are required to determine how these parameters
reflect outcomes over a larger spectrum of kidney cada-
veric transplants.
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